Physician profile
Vickie Hug
NPI 1235116781
$8,593.96
in general payments reported to CMS, 2019-2025
36 companies · $885 in 2025
The $885 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,477 · 2020: $1,037 · 2021: $1,086 · 2022: $1,427 · 2023: $1,404 · 2024: $1,278 · 2025: $885.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,567.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,567.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,881.20 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $1,354.33 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $953.45 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $644.93 | 2019-2025 | Jardiance, Tradjenta |
| Janssen Pharmaceuticals, INC | $423.55 | 2019-2022 | |
| Pfizer INC. | $417.31 | 2019-2025 | |
| Glaxosmithkline, LLC. | $377.85 | 2021-2025 | Shingrix, Arexvy |
| Amarin Pharma, INC. | $304.91 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $258.35 | 2025 | |
| Abbvie INC. | $218.40 | 2020-2023 | |
| Exact Sciences Corporation | $198.70 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $190.04 | 2019-2024 | Gardasil, Gardasil 9, Capvaxive |
| Amgen INC. | $184.63 | 2022-2025 | Repatha, Otezla, Repatha |
| Boston Scientific Corporation | $177.24 | 2023-2024 | Watchman Flx |
| Takeda Pharmaceuticals U.S.A., INC. | $168.98 | 2019-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $127.97 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $94.60 | 2023-2024 | Quviviq |
| Allergan, INC. | $87.79 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $70.76 | 2019-2021 | |
| Eisai INC. | $68.88 | 2019-2020 | |
| Astellas Pharma US INC | $67.65 | 2019-2025 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $44.14 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $31.55 | 2023-2024 | Eliquis |
| Therapeuticsmd, INC. | $29.09 | 2019 | |
| Acarix USA INC. | $28.38 | 2023-2024 | Cadscor System |
| Biohaven Pharmaceuticals, INC. | $25.53 | 2021 | |
| Abbott Laboratories | $20.57 | 2024 | Freestyle Libre 3 |
| Bausch Health US, LLC | $19.99 | 2023 | Aplenzin |
| Corium, LLC | $16.91 | 2023 | Azstarys |
| Genzyme Corporation | $16.39 | 2025 | |
| Ibsa Pharma INC. | $16.22 | 2025 | Flector, Licart, Tirosint |
| Nalpropion Pharmaceuticals LLC | $16.02 | 2019 | |
| Xeris Pharmaceuticals, INC. | $15.63 | 2023 | Gvoke Hypopen |
| Dermira, INC. | $15.37 | 2020 | |
| Hikma Pharmaceuticals USA | $13.55 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vickie Hug listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.